The treatment of advanced HCC has benefited from the approval of multiple novel therapeutic agents, including anti-VEGF targeted agents (sorafenib, regorafenib, lenvatinib, cabozantinib, ramucirumab, bevacizumab) and immune checkpoint inhibitors (nivolumab, pembrolizumab, atezolizumab, and ipilimumab). This evidence concerns the gene VEGFA and hepatocellular carcinoma.